Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Darolutamide vs capecitabine in androgen receptor–positive triple-negative advanced breast cancer
2017-002284-18Phase 2Active
- Sponsor
- Unicancer
- Start
- Oct 2017
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial in breast cancer comparing Darolutamide arm with Capecitabine arm (2 arms). Primary endpoints: Clinical benefit rate at 16 weeks (darolutamide arm) and Clinical benefit rate at 16 weeks (capecitabine arm). Started Oct 2017; status: active.
02
Drugs
darolutamidecapecitabine
03
Conditions
breast cancer
Beyond the preview
Go deeper on 2017-002284-18.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-002284-18.